At a glance
ClinicalIndex Comparison RecordN/ACompleted· 319 enrolled
Drug / intervention
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy (2IQP)
In Brief
A clinical study evaluating t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM and Standard Therapy plus continuous glucose monitoring (CGM) for Type 2 Diabetes Treated With Insulin. Completed, enrolled 319 participants across 21 sites in 2 countries.
Detailed Summary
A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ+ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Treated With Insulin
CountriesCanada, United States
CollaboratorsJaeb Center for Health Research
Timeline
N/ACompletedFinished
202420252026
First PostedMar 2023
Enrollment StartJun 2023
Primary CompletionSep 2024
TodayJul 2026
First PostedMar 27, 2023
Enrollment StartJun 1, 2023
Primary CompletionSep 24, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.3 years ago
Interventions
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGMdevice
The t:slim X2 insulin pump with Control-IQ+ technology, used with the Dexcom G6 CGM.
Standard Therapy plus continuous glucose monitoring (CGM)device
Standard therapy is continuation of pre-study basal-bolus insulin delivery method, plus use of Dexcom G6 CGM.